Top Page
SS Innovations International
(NASDAQ:SSII)
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
SS Innovations International Business Overview & Revenue Model
SS Innovations International Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.57M | 20.65M | 5.88M | 1.46M | 0.00 | 0.00 |
| Gross Profit | 16.20M | 8.45M | 713.45K | 489.59K | -18.79K | -37.43K |
| EBITDA | -13.12M | -17.74M | -20.26M | -5.31M | -1.47M | -1.09M |
| Net Income | -17.11M | -19.15M | -20.94M | -5.60M | -1.48M | -1.12M |
Balance Sheet | ||||||
| Total Assets | 69.58M | 42.39M | 25.48M | 6.98M | 428.61K | 317.87K |
| Cash, Cash Equivalents and Short-Term Investments | 11.71M | 466.50K | 7.03M | 217.18K | 405.77K | 160.71K |
| Total Debt | 12.68M | 18.20M | 8.22M | 8.27M | 145.00K | 195.00K |
| Total Liabilities | 29.93M | 28.93M | 11.18M | 9.66M | 287.28K | 1.19M |
| Stockholders Equity | 39.65M | 13.46M | 14.30M | -2.68M | 141.33K | -869.05K |
Cash Flow | ||||||
| Free Cash Flow | -22.35M | -10.16M | -15.81M | -1.44M | -363.03K | -94.54K |
| Operating Cash Flow | -20.29M | -9.50M | -15.36M | -5.99M | -363.03K | -90.54K |
| Investing Cash Flow | -2.07M | -661.48K | -453.33K | 240.82K | 38.15K | -44.00K |
| Financing Cash Flow | 28.20M | 9.43M | 22.80M | 5.90M | 569.95K | 266.77K |
SS Innovations International Technical Analysis
SS Innovations International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.24B | 19.40 | 6.60% | 2.00% | 4.69% | -51.57% | |
61 Neutral | $1.50B | -7.24 | -109.73% | ― | 17.87% | -57.03% | |
61 Neutral | $2.16B | -26.15 | -338.19% | ― | 24.76% | -10.41% | |
58 Neutral | $2.21B | -192.36 | -2.45% | ― | 9.81% | -1067.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.11B | -90.16 | -43.42% | ― | 159.43% | 67.42% | |
45 Neutral | $985.34M | -1.96 | -38.71% | ― | 4.99% | -7151.40% |
SS Innovations International Corporate Events
On November 13, 2025, Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations International, participated in an interview with Nasdaq’s Live From MarketSite. The interview was later published on December 16, 2025, and is available on both Nasdaq’s and the company’s websites. The information from the interview is considered ‘furnished’ and not ‘filed’ under the Securities Exchange Act of 1934, meaning it is not subject to the liabilities of that section.
On December 8, 2025, SS Innovations International announced the submission of a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple specialties such as general, urological, and cardiac surgeries. This strategic move aims to introduce the cost-efficient system to the U.S. market, enhancing its appeal to hospitals and surgeons, particularly in underserved communities. The company is also progressing towards obtaining a European Union CE marking certification by the first half of 2026. As of November 30, 2025, the SSi Mantra has been installed in 138 systems across eight countries, with over 7,300 surgical procedures performed, highlighting its growing global footprint.
SS Innovations International has released an updated company presentation for November 2025, highlighting their growth and strategic plans. The company has seen significant sales growth and is expanding its global presence, with the SSi Mantra system already marketed in eight countries. The presentation underscores the company’s commitment to improving surgical robotics technology and its potential impact on the healthcare industry.
On November 6, 2025, SS Innovations International announced the successful completion of the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC). This compact and portable console allows telesurgeries to be performed from various locations, including physician offices, without the need for a full operating room. The milestone surgery was conducted by Dr. Sudhir Srivastava from New Delhi, India, on a patient in Jaipur, India, highlighting the TSC’s ability to extend surgical expertise remotely. This development is expected to enhance patient access to surgical care and provide hospital networks with greater flexibility.
On October 28, 2025, SS Innovations International announced its third-quarter financial results, reporting a 192.5% increase in revenue to $12.8 million, driven by higher sales of the SSi Mantra 3 unit. Despite a net loss of $3.7 million, the company saw significant growth in installations and surgeries, with a 350% increase in SSi Mantra installations compared to the previous year. The company is progressing towards regulatory milestones, including a 510(k) submission to the FDA and a European Union CE marking certification, indicating robust growth prospects.
On October 21, 2025, SS Innovations International announced that its executives, Dr. Sudhir Srivastava and Dr. Vishwa Srivastava, will participate in upcoming investor conferences, including the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025. These events will provide opportunities for one-on-one and small group meetings, and a live webcast of the Stifel presentation will be available on the company’s website. This participation underscores the company’s commitment to engaging with investors and stakeholders, potentially enhancing its industry positioning and visibility.
SS Innovations International has released an updated company presentation for October 2025, highlighting its growth and strategic plans. The company has seen significant expansion, with 125 SSi Mantra systems installed and over 6,000 surgeries performed across nine specialties. The presentation underscores the company’s commitment to global expansion, particularly into Europe and the United States, and its strategy for long-term sustainable growth. The leadership team, with a proven track record in surgical robotics, aims to leverage favorable industry trends and a growing market to enhance its positioning and deliver advanced surgical solutions.
SS Innovations International announced the successful completion of a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. This milestone is crucial for their anticipated 510(k) premarket notification submission to the FDA in the fourth quarter of 2025, which could potentially allow the SSi Mantra to be marketed in the U.S. by the first half of 2026. The company has installed 125 SSi Mantra systems across six countries, with over 6,000 surgical procedures performed, highlighting its growing global footprint.
On September 26, 2025, SS Innovations International announced the appointment of Naveen Kumar Amar as Chief Financial Officer, effective September 24, 2025. Mr. Amar, with over 27 years of global finance experience, brings a strong track record in building finance operations and successful businesses across diverse industries. His appointment is expected to support SS Innovations’ expansion of its advanced, cost-efficient SSi Mantra surgical robotic system and drive growth, enhancing shareholder value.